Randomized clinical studies assessing the pharmacokinetics and subjective effects of vuse alto electronic nicotine delivery systems.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

The US FDA recommends assessment of abuse liability (AL) for premarket tobacco product applications (PMTAs) to determine whether a new tobacco product is appropriate for the protection of public health (APPH).

To assess the AL and nicotine uptake of Vuse Alto electronic nicotine tobacco products (ENDS) which offer e-liquid pods that vary in nicotine concentration, the researchers conducted two clinical laboratory studies.

The primary objective of Study 1 was to assess measures of product abuse liability (AL) in real time during and following product use.

Why It Was Studied

Study 1 included high (usual brand [UB] cigarettes) and low abuse liability (nicotine gum) comparators.

Nicotine PK of Vuse Alto products were generally similar across the three nicotine concentrations and four flavors tested in these studies.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, open-label and crossover.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Being open-label, the Therapeutic nicotine (patch, non-peptide) study did not mask who received what.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

Nicotine PK of Vuse Alto products were generally similar across the three nicotine concentrations and four flavors tested in these studies.

The subject headings attached to it are Electronic Nicotine Delivery Systems, Nicotine, Heart Rate, Blood Pressure and Vaping.

Author keywords: Abuse liability, E-cigarettes, ENDS, Products, Subjective measures and Vuse Alto.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2025 (Scientific reports), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.